and thank morning for Tim. us. joining you, Good Thank you
Arens, Corporate Vice moment would our I CFO. Development President to quarter, of the introduce to like into and get take we Interim and Strategy a our Tim Before
a our through Tim of of acted Interim XXXX completed we of also the we in vitro for quarter and head this may that Tim commercialization the you recall, earlier performed years diagnostics process. six Prior Abbott of general unit to also is three Tim quarters our the manager recently seminal both in business last with internal from back DCB FP&A as and the year. three XXXX. was CFO acquisitions Some our led
to are you, acumen corporate and act as our CFO. to strategy contributions Tim interim key to glad our We Tim. business have Thank
to on quarter pleased our to strong our are objectives. meaningful third performance report advances Moving and we performance, strategic operating in
revenue solid reflect we performance results the XX% continue new operational with our over growing included $X.X million fiscal top-line as of This quarter our in third Our revenue generated from SurVeil to XXXX. results of and product million pipeline. agreement invest $XX.X We of Abbott.
diluted share We also third the of per non-GAAP quarter. reported earnings $X.XX in
as continue to Our business on opportunities. we our underlying core performed core well commercial execute
our As up to $XX for $XX the range fiscal million, a result, of range year. expectations previous we $XX are to the million million XXXX of to in million $XX be updating the revenue from for
today's an provide a Embolitech revised guidance share. diluted XXXX negative provide to our Tim of turn quarter to the assets a objectives. guidance The detailed share of On to negative loss call of earnings call, our And as financial expected quarter as I the of the and over range guidance. been $X.XX prior compared the during related development reflects in-process has charge of share We also will $X.XX progress I to negative overview $X.XX positive towards have then, updates third review now fiscal for achievements more a quarterly as to per from of our guidance updated per negative $X.XX guidance to share. will with per of results prior strategic substantially in a our $X.XX to $X.XX research diluted $X.XX per as expected increased per compared to than and loss from Non-GAAP performance. and share acquisition $X.XX revenue better well $X.XX the
call We the questions. will to open your take then
an for we you in February late with agreement As Abbott recall, worldwide many SurVeil commercialization will of announced Drug-Coated rights Balloon. for
the Balloon are and Abbott trials Abbott fistula approval the development, obtain agreements with and collaborate part of program, and Drug-Coated development. which also balloon the activities outside Separately, U.S. preclinical marketing regulatory including to our agreement, currently options will the the product on SurVeil supply and drug-coated As of AV to Abbott clinical we U.S. Europe. negotiate in below in received knee
prioritizing data which three tissue of Preclinical low on improve a distributed and of to coating and to built uniformity. balloon this resources technology times drug-excipient incidence a technology our effect concentration, medical proprietary we for shown a of durable earlier drug drug-coated downstream compared coating As drug place, for are is balloon and particulate unique SurVeil a next project. design drug-coated a support Abbott five arrangement and reflects leadership the manufactured as a remainder, to balloon. durable in With drug process formulation to includes vascular The involvement service SurVeil more industry target of devices. have a is generation using generations higher evenly
on development is well. and Our Abbott SurVeil team exceptionally collaboration for going ongoing with itself the partnership
to with by their excited to realize deep potential market working full together of disease. drug-coated balloon expertise artery in are worldwide peripheral their partnership SurVeil vascular And people will coverage. treat products we and the a with to look given We care our forward Abbott
three the strategic turn of I'll objectives the year. that to we outlined at beginning Now the
least AV use for delineate fiscal to distribution to and knee rigorous advance finalize products clinical to the to in a and the AV reminder, three or below either new two, product --if manner; our efficient fistula transcend and drug-coated in are in-human for or with a four at one strategy products. solutions further first programs; two, our potential pipeline balloon of regulatory trial securing proprietary XXXX and by R&D execute whole for commercialization file partners high-quality our As these clearances
the U.S. XXXX as well We're to sites our and end throughout including progressing all in quarter. program, For our Europe. actively the getting way by SurVeil, fiscal clinical for We progressed running and on the having it transcend of at initiated planned. is sites some up sites pivotal trial enrollment nicely clinical
transcend the available. the the of for DCB leg is Medtronic level peripheral upper complete expect XX IN.PACT This We to treatment up outside and to of trial at transcend patients SurVeil end is randomized as And market fiscal XXXX. commercially that generation studies to XXX in a reminder, evaluate Admiral disease with Drug-Coated clinical Balloon to the in the compare XX enroll the among artery the U.S. enrollment next the U.S. approximately X is of DCB, compared expected sites will first to sites by trial leader. This one
countries. to in initiation approval countries received a and agencies regulatory with site work to continue respective initiate to-date We secure in several have multiple to for clearance site
timing reporting our look However, country. both our U.S. further feedback we especially in forward on will obtained the regulatory initial assumptions the internationally progress filings We from taking to calls. into on clinical depend in each requirements and consideration sites upcoming in
filing XXX And We human study of continue and we're in to knee our the program studies at drug-coated with making for a remain the currently our fiscal balloons. sirolimus on for one these throughout trial. XXXX. working AV remainder least products human we the balloon for access of balloons readiness the the make will below first first in we're for through this first data fiscal to and for fistula for used We anticipate fiscal Further, in the expect continued human below And the XXXX. for coated preclinical track knee to that be package progress initiating expect drug-coated in determine progress used XXXX.
blocking to excellent of briefly recently assay Turning the our which of business, signal interferences, developments Matrix while intended has the Diluent risk IVD stability. MatrixGuard is significantly MatrixGuard maintained. assay three-year and we positives unsurpassed Diluent launched false provides reduces
whole Switching Diluent further market product of a of a our innovated solutions Embolitech. is In gears intellectual of efforts property an May, premier MatrixGuard single around global from from the commitment of technology the million we Thrombectomy With we and provider $XXX digits. our announced assay new be performance components platform high now acquisition the to in our related growing many manufacturability that and continue thrombectomy R&D pipeline. launch diagnostic improve to assays.
their this of ICU broad deep and thrombus. Embolitech likelihood However, thrombosis, and ability application, including innovation embolism arterial reducing technologies limitations that The to significantly The significant treat platform time complications the next-generation vascular neuroendovascular the vein eliminate technology's currently peripheral technology of available affect embolism, need and with potential the and and innovative that pulmonary especially of thrombolytics outcomes. thrombosis. bleeding recovery use for the patient organized
anticipated reduce of external offers solution the need is the technology providing the procedures time pipeline for and thrombosis. complex differentiated solutions. this to procedure to of portfolio excited equipment whole over We're this [indiscernible]. any addition, additional not addition does add the highly table and in treatment on it require thereby a significant technology it strengthens that for patient advances capital the to In current The this technology of our product out peripheral multiple
We solution products manufacturing our of pipeline. hydrophilic development absorb our and whole as and will use our a operations design technology technology coating this capabilities into we
a expectations and is regulatory executing we very excited with working first already XXXX. timeline approval team to quite and in Our an in test for prototypes of the half aggressive working initial currently to calendar our application be are is first submit technology the on and in methods
of interested are commercial agreements our process in products, who progressing commercially reviewing of towards have each Turning the now approval. regulatory products our received that approved to of pipeline are several we with parties
We each an continue for devices order exercise to commercial maximize our and potential the the of for appropriate deal in these patients to signed shareholders. appropriate
in quarter positive. treating of to coronary recall be clearance Early may continues Telemark and in received microcatheter you .XXX feedback second the overwhelmingly fiscal the patients peripheral As FDA XXXX. support cases clinician
calcified microcatheter X.XFr a The lubricity Surmodics' high an composite peripheral tapered outer opinion microcatheter and penetration going complex a ranging the lesion hydrophilic has Xtreme performed deliverability, combines together it has offers pristine with coronary profile a Telemark low from hydrophilic very kink Telemark performance coating And well tough excellent best-in-class lesions. very This in support down tough of resistance particulates. crossing. for offers microcatheter that As and and Surmodics' hands lesions. X.XFr cross-ability provide shaft through technology coating exceptional to especially pristine's for effective leaders key lesions. of diameter reminder,
this product assess the feedback clinician ongoing And strategic evaluation. in We clinical and for clinical who multiple to and our own guard are active in performance have coming the conducting experience to we parties continue continue their its to months. evolve
by parties. PTA undergoing .XXX clinical interested catheter balloon and is evaluation also Our both Surmodics
with quarter, user from these catheter feedback PTA we with encouraging clinician .XXX cases. collecting experience the During balloon continued extremely initial
are revenue fiscal product and XXXX. are in pleased generation this for still We targeting
serene chemistry are year, this hydrophilic of coating. .XXX We we headway advanced our our peripheral and to for products catheter, coating using and FDA In of received our in solutions clearance April also capabilities. measurable which development continuing make balloon design incorporates XXX(k)
XXXX, show CE As you devices hydrophilic calendar Mark on devices FDA the catheters both and uses providing crossing products of most will And to smooth confident crossing artery serene for Surmodics' technologies growing .XXX and for clinicians coating. both We're new and invasive minimally ultra-low product focus the and crossing our treatment. balloon effective class profile recall These late offer entry and processes clearance in lesion. combined that leveraging demonstrate next complex also proprietary and transitions unmatched also for disease we and best-in-class .XXX particulate. these .XXX best generation address deliverability solutions. and improving proprietary These these the tip our in to accessing hydrophilic need and for provide friction which received for peripheral achieve advanced tool for coating lesion with by catheter,
products will respective Looking and ahead, exciting further filings regulatory in build growth. us are work achieve in help we platform to calendar clearance the next on Surmodics for wave the product is and these been will and regulatory highlight have exciting an innovations which we These clearances achieved. targeting continue top-line time It I at XXXX. our of after
products relationships combining on innovator However, deliver enduring we solutions. track innovative our medical to device technology device a are best-in-class medical to our customer key leading and become by assets,
progress. We top-line by with achievements ongoing regulatory our clinical performance encouraged and are operational also combined
to Tim end double-digit XX% fiscal about consistent third I at more and will the well our on of sights margins outlook we of details as generating by fiscal of as for top-line results XXXX attainable. out remainder very or fiscal generating the EBITDA believe call and growth over goals some XXXX. Tim? all now provide to in Our calendar the XXXX quarter our XXXX by turn
